Navigation Links
PRC Government Grants High-Tech Status to AOBO Subsidiaries
Date:1/13/2009

NEW YORK, Jan. 13 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB) ("AOBO" or "the Company"), a leading marketer, distributor and manufacturer of pharmaceutical and healthcare products in China, today announced that the PRC government, led by the Ministry of Science and Technology of China, the Ministry of Finance and the State Administration of Taxation, jointly granted three of the company's subsidiaries, Heilongjiang Songhuajiang Pharmaceutical Co., Ltd. ("HSPL"), Changchun Xin'an Pharmaceutical Co., Ltd. ("CCXA"), and Three Happiness Bioengineering Co., Ltd. ("Three Happiness") high-tech enterprise status. Prior to today's announcement, AOBO's other two subsidiaries: Guangxi BOKE Pharmaceutical Co., Ltd. ("BOKE") and Guangxi Lingfeng Pharmaceutical Co., Ltd. ("GLP") were already approved for the designation from the local provincial government, and the Company anticipates finalizing the certification from the central government in the near future. With today's announcement, five of AOBO's subsidiaries, throughout different provinces, have received recognition to benefit from a 15 percent tax rate through 2011, at the subsidiary level. Additionally, according to the China Banking Regulatory Commission Guiding Opinions Number 94, companies with high-tech status are eligible for benefits in addition to the 15 percent tax rate, potentially including preferential treatment in obtaining other support from the government such as obtaining financial support from the PRC's special Technological Development Fund, and to receive competitive commercial bank loans and subsidized interest.

Mr. Tony Liu, Chairman and CEO of AOBO, stated, "Receipt of high-tech enterprise status further demonstrates the fundamental strength of our business particularly related to our proprietary products and innovation a
'/>"/>

SOURCE American Oriental Bioengineering, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Maureen Mo Zilly Joins the Varian Medical Systems Government Affairs Team as Director, Federal Affairs
2. Atlantica Bioenergy Task Force hosts industry and government leaders
3. SenesTech, Inc. Commences Product Registration Process With Australian Government
4. San Diego universities, government and industry rally around local Clean-Tech cluster
5. Isis Announces Award of Up to $8.4 Million in New Government Grants and Contracts to Its Ibis Biosciences Subsidiary for Pathogen Detection and Human Forensics
6. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
7. Enigma Diagnostics Announces an Award of GBP 1.8 Million From UK Government
8. Valley Baptist Health System Selects Concuitys ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers
9. Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene
10. CBO: Biogenerics Would Save Federal Government $6.6 Billion Over Ten Years
11. BioNeutral Laboratories Announces the Appointment of Stephen Browand as a Director to Head Military, Homeland Security and Governmental Affairs

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...RNewswire-FirstCall/ -- ,, 3Q09 Corporate Hi...M) E.U. Marketing Authorization to Astellas Pharma...cial readiness activities Expanded management tea... and Director, Commercial Operations Appointed Br...ommittee chairman , Upcoming 2009 Milestone...
(Date:11/6/2009)...FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NAS...nounced updated results from a Phase II study of i...etastatic to the lung in a poster presentation at ... Meeting held in Miami Beach, Florida, from Novemb...A Phase II Study of Intravenous REOLYSIN (Wild-typ...
(Date:11/6/2009)...da for Arrowhead’s 2010 Personalized Medicin...ace on February 22-24, 2010 in Philadelphia, has b...l highlight key issues in forming partnerships and...es. , Minneapolis, MN (PR...rsquo;s 2010 Personalized Medicine Partnerships C...
(Date:11/5/2009)...RNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNV...third quarter ended September 30, 2009. GenVec rep... for the three months ended September 30, 2009 com...re) in the comparable quarter of 2008. For the nin...ss was $14.1 million ($0.15 per share), compared t...
Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6
... Biosciences announces,an enhanced matching funds ...n in genomics. $1.75 million in matching funds is ... to each qualifying institution. The,Genomics Educ... streamlined,application process to help colleges ...ndergraduate students studying molecular biology a...
...n combats an,alarming rise in chronic diseases, th...rica (PhRMA) today released a new report on the ne...hat offer hope to millions,of patients., The repo...d,biotechnology companies - including several loca...tech medicines., Today,s report was released in M...
...ble Oils has reached a,key milestone in its effort...tunities for Montana farmers. The company received... a department of the Federal Drug,Administration, ...ot beef,cattle and growing swine up to 2 percent o... a by-product of camelina oil extraction., Sustai...
Other Biology Technology:New Report on 633 Biotechnology Medicines Under Development Released in Michigan 2New Report on 633 Biotechnology Medicines Under Development Released in Michigan 3Sustainable Oils Receives Regulatory Approval for Feeding Camelina Meal in Livestock Diets 2Sustainable Oils Receives Regulatory Approval for Feeding Camelina Meal in Livestock Diets 3
(Date:11/8/2009)... Ind. - Researchers at Purdue University have disc...fibers in spinal cord injuries using nano-spheres ...r an accident. , The synthetic "copolymer micell...in diameter, or roughly 100 times smaller than the...e been studying how to deliver drugs for cancer tr...
(Date:11/6/2009)...ration is now open for the Society of Intervention...gy (IO) Therapies" Webinar, which will provide the...treatment of liver tumors, kidney tumor ablation a...tion of physicians, scientists and allied health p...through pioneering advances in image-guided therap...
(Date:11/6/2009)...6 Auburn Hills, MI-based Law Enfor...talling its locker system and patent-pending Biome...Department of Health and Human Services, National ... The locker system will support the NIH,s entire p... nation,s medical research agency. The project is...
Breaking Biology News(10 mins):Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3Society of Interventional Radiology hosts oncology therapies Webinar, offers resources 2EPA grant to University of Chicago for research on food allergy triggers 9332 1Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis 52567 1Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis 52567 2Study in this Week 26apos 3Bs Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 52563 1Study in this Week 26apos 3Bs Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 52563 2Study in this Week 26apos 3Bs Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 52563 3
...hiny amber jewelry and a mucky Florida swamp have ...m that could be anywhere from 15 million to 130 mi...f Florida and the Museum of Natural History in Ber...quatic critters such as beetles and small crustace...the water from pine-like trees. Their findings are...
...ber 17, 2007. -- It all started as a graduate scho...ire to figure out why things live where they do, s...ive in different places? Ive been studying the dis...ears. So I even made this question the basis of my...s. , That burning desire led Neilson to develop t...
... the leading cause of death due to infectious dise...lion people are currently infected, and although m... occur. This paper by Denise Kirschner and colleag...ducts virtual clinical trials to examine the cause... (TNF) is a protein that facilitates cellcell comm...
Other Biology News:Scientists find how amber becomes death trap for watery creatures 2Scientists find how amber becomes death trap for watery creatures 3Neilson member of Nobel Prize-winning panel of scientists 2
...highly photostable FluoSpheres microspheres have e...ions requiring probes that can deliver a strong si...ule-labeled microspheres have hydrophobic regions ... in some applications. This nonspecific binding ca...
DNA Polymerase I Large (Klenow) Fragment from Invitrogen
...Proteinase K is a highly active and stable endopep...ed from the fungus T. album. It cleaves peptide bo...ituted hydrophobic aliphatic and aromatic amino ac...roteinase K is useful in purifying high molecular ...
Combiplate 8 from Thermo Scientific
Biology Products: